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Objective: Risk of death in dialysis patients is lowest with arteriovenous ﬁstulas (AVFs), followed by arteriovenous grafts
(AVGs) and then intravenous hemodialysis catheters (HCs). Our aim was to analyze the effects of age at hemodialysis
initiation on mortality across different access types.
Methods: All patients $18 years in the United States Renal Data System between the years 2006 and 2010 were analyzed.
Spline modeling and risk-adjusted Cox proportional hazard models were used to analyze the effect of age on mortality for
ﬁrst dialysis access with AVF vs AVG vs HC.
Results: The study analyzed 507,791 patients (63.4 6 0.02 years; 56.5% male; 40.9% mortality; follow-up, 1.57 6 1.36
years). Increasing age was a signiﬁcant predictor of overall mortality (adjusted hazard ratio [aHR], 1.03; P < .001).
Compared with patients with HCs (n [ 418,932), overall risk-adjusted mortality was lowest in patients with AVFs
(n[71,316; aHR,0.63;P< .001) followedbyAVGs (n[17,543; aHR,0.83;P< .001).AVFwas superior to bothHCand
AVGfor all age groups (P< .001).However, therewas a signiﬁcant change in the relative efﬁcacy ofAVGat ages 48 years and
89 years based on spline modeling; there were no signiﬁcant differences comparing adjusted mortality with AVG vsHC for
patients aged 18 to 48 years or for patients >89 years, but AVG was superior to HC for patients 49 to 89 years of age
(aHR,0.811;P< .001).Themortalitybeneﬁt ofAVFwas consistently superior to thatofAVGandHCforpatientsof all ages
(all, P < .001).
Conclusions: AVF is superior to AVG and HC regardless of the patient’s age, including in octogenarians. In contrast, the
mortality beneﬁt of AVG over HC may not apply to younger (18-48 years) or older (>89 years) age groups. All patients
18 to 48 years should receive AVF for dialysis access whenever possible. (J Vasc Surg 2015;61:449-56.)A number of prior studies have evaluated the beneﬁts
of initiating dialysis with an arteriovenous ﬁstula (AVF) vs
arteriovenous graft (AVG) or intravenous hemodialysis
catheter (HC), demonstrating overwhelming favor of
AVF.1-8 As a result, the National Vascular Access Improve-
ment Initiative, later renamed the Fistula First Break-
through Initiative, was started in 2003 in an attempt to
increase AVF use and to reduce HC use for dialysis access.9
Consistent with this initiative, the National Kidney Foun-
dation Kidney Disease Outcomes Quality Initiative pub-
lished guidelines in 2006 endorsing the creation of an
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is recommended.11 Despite these initiatives, incident AVF
prevalence in the United States remains less than 20%12
and has shown minimal improvement in recent years
(Malas et al, in press).
One potential reason that may be contributing to the
low incident AVF rates is the perception that permanent
dialysis access is not necessary within certain patient popu-
lations. For example, the Kidney Disease Outcomes Qual-
ity Initiative calls for permanent dialysis only among
pediatric patients who are expected to require dialysis for
longer than 1 year, with the thought that many young pa-
tients are listed for prompt renal transplantation and there-
fore can be bridged appropriately with an HC.13 Similarly,
AVFs are often avoided in older populations, with the
thought that elderly patients have a higher risk of death
before starting dialysis and on dialysis initiation, making
the beneﬁts of AVF over AVG or HC less clear.14,15
Although a handful of studies have investigated the
mortality rates with different forms of dialysis access within
speciﬁc young16-20 and elderly populations,4,21-24 there are
minimal data evaluating variations in mortality across a
wide range of ages. Our aim was to analyze the effects of
age and initial dialysis access type on mortality.
METHODS
This study was a retrospective review of data from the
prospectively maintained United States Renal Data System449
Table I. Distribution of dialysis access method by age
category
AVF
(n ¼ 71,316),
No. (%)
AVG
(n ¼ 17,543),
No. (%)
HC
(n ¼ 418,932),
No. (%)
Age category
18-34 years 2070 (2.90) 446 (2.54) 20,723 (4.95)
35-44 years 4577 (6.42) 929 (5.30) 31,262 (7.46)
45-54 years 10,567 (14.8) 2259 (12.9) 62,789 (15.0)
55-64 years 17,175 (24.1) 4073 (23.2) 94,705 (22.6)
65-74 years 18,528 (26.0) 4668 (26.6) 97,559 (23.3)
75-84 years 14,962 (21.0) 4137 (23.6) 85,784 (20.5)
>84 years 3437 (4.82) 1031 (5.88) 26,110 (6.23)
AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; HC, hemodialysis
catheter.
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database, tracking each end-stage renal disease (ESRD) pa-
tient receiving renal replacement therapy within the United
States. Annual reports published since 1988 appear at
usrds.org and provide information on epidemiology, hospi-
talization, mortality, and cost, among other parameters.25
The USRDS maintains a robust database on every ESRD
patient by integrating patient-speciﬁc data from the Cen-
ters for Medicare and Medicaid Services (CMS), Centers
for Disease Control and Prevention, United Network for
Organ Sharing, and ESRD networks. The Johns Hopkins
Hospital Institutional Review Board and the USRDS
approved this study before its initiation. Data from the
USRDS are in the public domain, and thus informed con-
sent was not required for this study.
All patients in the USRDS database aged $18 years
who initiated dialysis between 2006 and 2010 were
included. Patients missing data pertaining to age or initial
dialysis access type, as well as those who stated dialysis
before 2006 or received a kidney transplant during the
course of the study period (as determined by records
from the United Network for Organ Sharing), were
excluded. In addition, we excluded all patients who died
within 90 days of initiating dialysis because it takes up to
90 days for patients to obtain complete Medicare coverage,
resulting in a high likelihood that dialysis access type and
mortality were skewed in this population. Data on patient
characteristics, including baseline demographics, comor-
bidities, etiology of ESRD, access to nephrologist care,
and initial dialysis access type, were collected from CMS
Form 2728, End Stage Renal Disease Medical Evidence
Report. Data on patient mortality were collected from
CMS Form 2746, ESRD Death Notiﬁcation Form.
Statistical methods. The aim of this study was to
compare the association between age and initial dialysis ac-
cess type with all-cause mortality. As such, all patients were
classiﬁed into one of three study groups for analysis: AVF,
AVG, and intravenous HC. Patients with HC and a
maturing AVF or AVG at the time of dialysis initiation
remained classiﬁed as HC on the basis of our prior work
that demonstrated a signiﬁcant mortality beneﬁt with initial
AVF or AVG over HC with maturing AVF or AVG (Malas
et al, in press) and in accordance with prior work investi-
gating mortality outcomes based on initial dialysis access
used.21 All patients were classiﬁed by an intention-to-treat
approach, meaning that they were classiﬁed as AVF vs AVG
vs HC by the type of dialysis access with which they initi-
ated dialysis; changes in access type during the course of
the study period were not accounted for.
Descriptive (mean 6 standard error of the mean or
count with percentage) and univariable (analysis of variance
and Pearson c2 tests) statistics were used to evaluate base-
line characteristics and to compare overall mortality be-
tween study groups. The overall effect of age on
mortality was assessed by univariable and multivariable
Cox proportional hazard models. The covariates included
in the adjusted models were predictive of mortality in the
USRDS population on the basis of univariable analysesand likelihood ratio tests and included dialysis access
type, gender, body mass index (BMI), insurance status
before ESRD coverage, comorbidities (congestive heart
failure, atherosclerotic heart disease, cerebrovascular dis-
ease, peripheral vascular disease, hypertension, diabetes
mellitus, chronic obstructive pulmonary disease, cancer),
smoking history, alcohol and drug dependence, ability to
ambulate, etiology of ESRD, and access to nephrologist
care.
To more fully explore the effects of age and dialysis ac-
cess type on mortality, we used risk-adjusted Cox propor-
tional hazard models to test the risk of mortality for AVF
and AVG vs HC for incrementally increasing age groups
as categorized by 10- and then 5-year increments. On
the basis of an apparent interaction between age and mor-
tality among younger and older patients, we then per-
formed spline modeling to estimate the age at which the
relative mortality beneﬁts of different forms of dialysis ac-
cess changed. The spline technique applies a piece-wise
approach to the evaluation of points (knots) at which sig-
niﬁcant changes occur in the trend of the age-mortality
function.26 Differences in mortality at certain age cutoffs
as identiﬁed by the spline model were explored with multi-
variable analyses of the slopes of the spline graph for each
treatment before and after each designated age cutoff.
Multivariable Cox proportional hazard models using mov-
ing averages 62 years were then employed to estimate the
precise age at which there was an inﬂection point in the
mortality beneﬁt of a speciﬁc treatment and to describe
the adjusted hazard ratios (aHRs) for mortality for AVF
and AVG vs HC over each age range. For all analyses,
HC served as the reference group.
All data analyses were performed with Stata 12.1 statis-
tical software (StataCorp, College Station, Tex), with a
level of P < .05 denoting statistical signiﬁcance.
RESULTS
Patient characteristics. During the 5-year study
period, 553,064 patients initiated dialysis in the USRDS
database. Of these, 45,273 (8.19%; AVF, 2262; AVG, 874;
HC, 41,773) died within 90 days and were excluded,
leaving a total of 507,791 patients for analysis (mean age,
Table II. Patient characteristics by dialysis access method
AVF (n ¼ 71,316), No. (%) AVG (n ¼ 17,543), No. (%) HC (n ¼ 418,932), No. (%)
Age, years, mean 6 SEM 64.1 6 0.05 65.5 6 0.10 63.2 6 0.02
BMI, kg/m2, mean 6 SEM 29.3 6 0.03 29.4 6 0.06 28.9 6 0.01
Gender
Male 64.2 44.1 55.7
Female 36.8 55.9 44.4
Race
White 56.3 43.2 51.5
Black 26.1 41.4 29.2
Hispanic 11.5 10.1 14.1
Other 6.11 5.28 5.16
Insurance status
None 4.02 4.32 8.49
Medicaid 9.35 11.5 12.1
Private 61.8 66.1 58.0
Medicare, Veterans Affairs 24.8 18.2 21.4
ESRD etiology
Diabetes 48.3 51.2 45.1
Hypertension 29.4 30.0 28.7
Glomerulonephritis 7.86 5.33 5.65
Polycystic kidney disease 4.43 2.47 1.23
Other urologic 1.18 1.27 1.43
Other 6.25 7.09 13.8
Unknown 2.58 2.66 4.09
Comorbidities
CHF 26.6 31.7 35.1
ASHD 22.3 22.4 21.8
CVD 8.99 12.0 9.79
PVD 13.4 15.8 14.5
Hypertension 89.1 87.6 84.2
Diabetes
No 46.5 42.6 46.2
Diet controlled 5.26 5.64 4.93
Oral medication 13.3 13.3 11.9
Insulin dependent 34.9 38.5 37.0
COPD 7.47 8.22 9.94
Current smoker 5.95 5.88 6.43
Cancer 6.87 7.03 7.83
Alcohol dependence 0.89 0.99 1.91
Drug dependence 0.85 1.29 1.57
Inability to ambulate 3.02 6.44 8.27
Nephrologist care 95 85.2 55.9
ASHD, Atherosclerotic heart disease; AVF, arteriovenous ﬁstula; AVG, arteriovenous graft; BMI, body mass index; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVD, cerebrovascular disease; ESRD, end-stage renal disease; HC, hemodialysis catheter; PVD, peripheral vascular
disease; SEM, standard error of the mean.
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1.36 years). Of these, hemodialysis was initiated with AVF
in 14.0% (n ¼ 71,316), AVG in 3.45% (n ¼ 17,543), and
HC in 82.5% (n ¼ 418,932) (Table I). Overall mortality
was 40.9% (n ¼ 207,896). A complete summary of patient
characteristics stratiﬁed by incident dialysis access type is
provided in Table II.
Association between dialysis access method and
mortality. As we previously demonstrated in this patient
population (Malas et al, in press), initial dialysis access
type was a signiﬁcant predictor of mortality. On univariable
analysis, mortality was signiﬁcantly lower with AVF (HR,
0.63; 95% conﬁdence interval [CI], 0.62-0.64) and AVG
(HR, 0.83; 95% CI, 0.81-0.85) compared with HC (P <
.001). Multivariable analysis adjusting for age, gender,
BMI, insurance status, comorbidities, etiology of ESRD,
and nephrologist access similarly showed a signiﬁcantlylower mortality risk with AVF (aHR, 0.65; 95% CI,
0.64-0.66) and AVG (aHR, 0.82; 95% CI, 0.80-0.84)
compared with HC (P < .001).
Association between age and mortality. Mean age at
the time of dialysis initiation was lowest for patients with
HC (63.2 6 0.02 years), followed by AVF (64.1 6
0.05 years) and AVG (65.5 6 1.04 years) (P < .001).
Increasing age was a signiﬁcant predictor of mortality on
both univariable (HR, 1.04; 95% CI, 1.04-1.04) and multi-
variable (aHR, 1.03; 95% CI, 1.03-1.03) analysis adjusting
for dialysis access type, gender, BMI, insurance status,
comorbidities, etiology of ESRD, and nephrologist access
(both, P < .001).
Based on 10-year age categories, the mortality beneﬁt
with AVF was superior to that with both HC and AVG
for all age groups (P < .001; Fig 1), including among
the elderly ($75 years of age; aHR, 0.66; 95% CI,
Fig 1. Risk-adjusted mortality based on age and ﬁrst dialysis access type. Based on 10-year age categories, arterio-
venous ﬁstula (AVF) was superior to both hemodialysis catheter (HC) and arteriovenous graft (AVG) for all age
groups, including among the elderly (all, P < .001). There was no signiﬁcant mortality beneﬁt with AVG vs HC for
patients aged 18 to 44 years (P > .18). However, AVG was superior to HC for all age groups $45 years.
Table III. Risk-adjusted mortality hazard ratios (HRs) for arteriovenous ﬁstula (AVF) and arteriovenous graft (AVG) vs
hemodialysis catheter (HC) by 5-year age category
Age category
Percentage mortality, No. (%) Adjusted mortality, HR (95% CI)
AVF (32.4%)
(n ¼ 23,086)
AVG (43.1%)
(n ¼ 7558)
HC (48.1%)
(n ¼ 201,572) AVF vs HC P value AVG vs HC P value
18-24 years 26 (6.8) 9 (11.5) 652 (11.6) 0.874 (0.560-1.36) .552 0.852 (0.399-1.82) .678
25-29 years 49 (8.1) 26 (21.0) 1053 (16.2) 0.504 (0.346-0.733) <.001 0.962 (0.605-1.529) .869
30-34 years 96 (8.9) 46 (18.9) 1712 (19.2) 0.534 (0.414-0.690) <.001 0.881 (0.621-1.250) .477
35-39 years 220 (12.3) 84 (22.1) 2731 (21.3) 0.747 (0.630-0.887) <.001 0.874 (0.668-1.144) .328
40-44 years 390 (14.0) 125 (22.8) 4628 (25.1) 0.596 (0.521-0.682) <.001 0.906 (0.735-1.118) .359
45-49 years 697 (15.9) 252 (27.2) 7810 (29.5) 0.615 (0.557-0.678) <.001 0.875 (0.750-1.020) .09
50-54 years 1215 (19.7) 356 (26.7) 12,302 (33.9) 0.687 (0.639-0.739) <.001 0.693 (0.607-0.791) <.001
55-59 years 1816 (22.9) 612 (32.6) 17,424 (38.5) 0.609 (0.572-0.647) <.001 0.857 (0.778-0.994) .002
60-64 years 2500 (27.1) 823 (37.5) 21,419 (43.3) 0.674 (0.640-0.710) <.001 0.887 (0.815-0.965) .005
65-69 years 3059 (32.6) 986 (42.0) 24,916 (50.6) 0.652 (0.622-0.683) <.001 0.842 (0.780-0.908) <.001
70-74 years 3525 (38.5) 1149 (50.0) 28,040 (58.0) 0.635 (0.607-0.663) <.001 0.815 (0.759-0.875) <.001
75-79 years 3938 (46.1) 1257 (54.4) 30,753 (65.5) 0.661 (0.635-0.689) <.001 0.782 (0.731-0.836) <.001
80-84 years 3431 (53.4) 1129 (61.9) 27,825 (71.7) 0.654 (0.625-0.684) <.001 0.774 (0.719-0.832) <.001
85-89 years 1778 (60.8) 560 (66.3) 15,905 (76.8) 0.681 (0.640-0.725) <.001 0.811 (0.733-0.897) <.001
>89 years 346 (67.6) 144 (77.4) 4437 (82.3) 0.684 (0.595-0.787) <.001 1.045 (0.850-1.284) .677
CI, Conﬁdence interval.
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beneﬁt with AVG vs HC for patients aged 18 to 34 years
(aHR, 0.92; 95% CI, 0.71-1.19; P ¼ .52) or 35 to 44 years
(aHR, 0.90; 95% CI, 0.76-1.06; P ¼ .19). However, AVG
was superior to HC for all age groups$45 years (P < .001;
Fig 1).
When age category was broken down further into
5-year groups, adjusted mortality was similar for patients
18 to 25 years regardless of initial dialysis access type (all,
P > .55; Table III). There were also no signiﬁcant differ-
ences comparing adjusted mortality with AVG vs HCfor patients aged 25 to 44 years (aHR, 0.90; 95% CI,
0.78-1.04; P ¼ .14) or for patients $89 years (aHR,
1.05; 95% CI, 0.85-1.28; P ¼ .67). For patients aged 45
to 49 years, there was a trend toward beneﬁt with AVG
vs HC, but this was not statistically signiﬁcantly (aHR,
0.88; 95% CI, 0.75-1.02; P ¼ .09). AVF was superior to
AVG and HC for all patients $25 years (aHR, 0.65; 95%
CI, 0.64-0.66; P < .001).
Results of spline modeling. Based on the multivari-
able regression results, we performed spline modeling to
estimate the age at which the relative mortality beneﬁts
Fig 2. Adjusted spline model to determine age cutoffs where the
relative beneﬁts of arteriovenous ﬁstula (AVF) vs arteriovenous
graft (AVG) vs hemodialysis catheter (HC) changed. Visual rep-
resentation of the adjusted spline model suggested a potential
change in beneﬁt with different forms of dialysis access at ages 25,
48, and 89 years. For HC, mortality was highest among patients 18
to 25 years. For AVG, there was a signiﬁcant change in the relative
mortality beneﬁt vs HC at ages >48 years and >89 years (both,
P< .001); there were no signiﬁcant differences comparing adjusted
mortality with AVG vs HC for patients aged 18 to 48 years or for
patients >89 years (P $ .069), but AVG was superior to HC for
patients 49 to 89 years of age (P < .001). The mortality beneﬁt of
AVF was consistently superior to that of AVG and HC for patients
of all ages (all, P <.001). ESRD, End-stage renal disease.
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resentation of the adjusted spline model suggested a
change in beneﬁt with different forms of dialysis access at
ages 25, 48, and 89 years (Fig 2).
For HC, the slope of the spline graph for mortality was
signiﬁcantly higher for patients aged 18 to 25 years
compared with older age groups (slope, 1.10; 95% CI,
1.07-1.14; P < .001). The slope of the line was relatively
stable for patients aged >25 to 48 years (slope, 1.02;
95% CI, 1.02-1.02) and 49 to 89 years (slope, 1.03; 95%
CI, 1.03-1.03), with a slight increase in patients
>89 years (slope, 1.06; 95% CI, 1.04-1.07). These data
suggest that mortality with HC was increasing most rapidly
as a function of age among patients 18 to 25 years, fol-
lowed by patients >89 years and then patients 49 to
89 years and patients 26 to 48 years.
For AVF, the slope of the spline graph was slightly less
steep for patients aged 18 to 25 years compared with older
ages (slope, 0.90; 95% CI, 0.80-1.01; P ¼ .07), although
this was not statistically signiﬁcant. Regardless, the mortal-
ity beneﬁt of AVF was consistently superior to that of AVG
and HC for patients aged 18 to 48 years (overall aHR,
0.62; 95% CI, 0.58-0.67; P < .001) and >48 years (overall
aHR, 0.65; 95% CI, 0.64-0.67; P < .001), including
among patients >89 years (aHR, 0.69; 95% CI, 0.60-
0.79; P < .001; Fig 3, A). These data suggest that the mor-
tality beneﬁt of AVF was consistently superior to that of
AVG and HC for patients of all ages.
For AVG, the slope of the spline graph line demon-
strated a signiﬁcant decrease relative to HC at age
>48 years compared with younger ages (slope, 0.98; 95%
CI, 0.97-0.99; P ¼ .02) and a signiﬁcant increase relative
to HC at age >89 years (slope, 1.07; 95% CI, 1.01-1.15;
P ¼ .04). Consistent with this pattern, there was a signiﬁ-
cant change in the relative mortality beneﬁt of AVG vs HC
at ages >48 years and >89 years (both, P < .001; Fig 3, B).
There were no signiﬁcant differences in comparing
adjusted mortality with AVG vs HC for patients aged 18
to 25 years (aHR, 0.90; 95% CI, 0.81-1.01; P ¼ .07) or
26 to 48 years (aHR, 0.90; 95% CI, 0.78-1.04; P ¼
.14), but AVG was superior to HC for patients 49 to
89 years (aHR, 0.81; 95% CI, 0.79-0.84; P < .001). For
patients >89 years of age, adjusted mortality was similar
between AVG and HC (aHR, 1.05; 95% CI, 0.85-1.28;
P ¼ .67). These data suggest that the mortality beneﬁts
of AVG are restricted to patients aged 49 to 89 years.
DISCUSSION
Despite the overwhelming data and subsequent call for
action to preferentially use AVF over AVG, with HC as a
last resort,1-8 the nuances of different forms of dialysis access
within particular patient populations are not well described.
Few prior studies have looked at the beneﬁts of AVF vs
AVG vs HC over a continuous range of patient ages.
In general, most reports focus on the outcomes beneﬁts
of AVF and AVG within the adult population as a whole,
adjusting for age as a potential confounding variable
but never explicitly addressing the signiﬁcance of howage affects mortality.2-4,6,8,27 Other studies have attempted
to address age-based differences in dialysis access mortality
by evaluating patients in a binary division of “elderly” vs
“younger,” the former of which has varied anywhere
from $67 years4,21,22 to $70 years21 to $80 years (“octo-
genarian”)23,24 to $90 years (“nonagenarian”).21,22
In the current study, we aimed to analyze the effects of
age and initial dialysis access type on all-cause mortality
over a broader age spectrum. We demonstrate that the pre-
viously reported mortality outcomes with permanent access
compared with HC are age dependent. Speciﬁcally, among
patients initiating dialysis access with AVG, there was a sig-
niﬁcant change in the relative mortality beneﬁt vs HC at
ages >48 years and >89 years. We observed no signiﬁcant
differences in comparing adjusted mortality with AVG vs
HC for patients aged 18 to 48 years or for patients
>89 years, but AVG was superior to HC for patients
>48 to 89 years of age. Overall, these data suggest that
the mortality beneﬁts of AVG over HC are restricted to pa-
tients aged >48 to 89 years. This is the ﬁrst study that we
know of to demonstrate a changing beneﬁt with AVG
depending on the patient’s age. In contrast, the mortality
beneﬁt of AVF was consistently superior to that of AVG
and HC for patients of all ages. Use of HC in patients
18 to 25 years resulted in a higher rate of mortality
compared with other age groups.
Our ﬁnding that the slope of the mortality hazard ratio
line was highest in patients aged 18 to 25 years is in line
with observations reporting that a consistent beneﬁt with
Fig 3. Mortality beneﬁts of arteriovenous ﬁstula (AVF) and arteriovenous graft (AVG) vs hemodialysis catheter (HC)
for different age categories. A, The mortality beneﬁt of AVF was consistently superior to that of HC for patients of all
ages (all, P < .001). B, There were no signiﬁcant differences comparing adjusted mortality with AVG vs HC for pa-
tients aged 18 to 48 years (P $ .07) or for patients aged >89 years (P ¼ .67), but mortality with AVG was superior to
that with HC for patients aged 49 to 89 years (P < .001). HR, Hazard ratio.
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populations.16,28-30 Similar to ﬁndings in adults, AVFs have
been shown to have signiﬁcantly higher access survival rates
and lower infection and access malfunction hospitalization
rates than HC among patients <21 years of age.29,31 There
is some evidence in the pediatric population to suggest that
both 1- and 5-year survival is similar with AVF (74% and
59%, respectively) and AVG (96% and 40%, respectively)16
and signiﬁcantly better than survival with HC (27%-
62%).17-20 These ﬁndings were consistent regardless of
the patient’s weight or age.16
In our study, we do not address the association be-
tween access type and mortality in patients younger than
18 years, but we do see a consistent beneﬁt with AVF
over both AVG and HC in all age groups based on spline
modeling, including those at the younger (18-25 years)
and older (>89 years) extremes of age. Contrary to the re-
sults reported in children, we did not observe a beneﬁt of
AVG over HC within the groups aged 18 to 25 years or
26 to 48 years. The relative number of patients in the
younger age group was relatively small compared with
the rest of the cohort. However, our study was much larger
than previously published studies reporting outcomes in
young adult or pediatric populations.16,29,31 In addition,
we are evaluating the association between initial dialysis ac-
cess catheter type and mortality rather than longitudinal
trends over time. Changes in vascular access type are
common in the ﬁrst 6 months after starting of dialysis,8
probably because of the 4- to 6-week perioddor up to
6-month period in younger and smaller patientsdthat is
often required for AVF maturation as well as unrealized
needs for prolonged dialysis access in patients listed for kid-
ney transplantation.28 It is also possible that the stenosis,
infection, and thrombosis rates with AVGs are different
in young adults compared with pediatric patients, making
patients in the 18- to 48-year age group more susceptible
to graft failure and thus a reduced beneﬁt with AVG over
HC. Additional analyses assessing the mortality beneﬁt of
AVF vs AVG vs HC that allow the incorporation of data
describing access changes over time as well as analysespertaining to cause of death (eg, renal-related, infection-
related) would likely be beneﬁcial in this population.
Regardless, the apparent lack of beneﬁt with AVG over
HC in the younger population suggests that patients
aged 18 to 25 years who are not candidates for AVF place-
ment may be more appropriately served by receiving an
expedited transplant rather than permanent dialysis access
with a graft conduit. The potential policy implications of
this approach as well as its appropriateness within the pedi-
atric population (<18 years of age) remain to be
determined.
Within the older population, the association between
dialysis access type and all-cause mortality is less clear.14
In 2013, DeSilva et al evaluated mortality based on initial
dialysis access type placement in 115,425 patients
$67 years and showed a signiﬁcant detriment with HC
(mortality HR, 1.77) but no differences in survival
comparing AVG vs AVF (mortality HR, 1.05).22 When
the authors stratiﬁed the study cohort into smaller age
groups, they demonstrated a signiﬁcant beneﬁt with AVF
over both AVG and HC among patients aged 67 to
69 years, but outcomes with AVF and AVG were similar
among patients 79 to 89 years and $90 years. Initial dial-
ysis access with HC was associated with worse outcomes
across all age groups. However, other studies have reported
improved survival outcomes with AVF over AVG and HC
in a range of elderly populations.4,21,23,24,32 Xue et al re-
ported mortality beneﬁts of initiating dialysis with AVF
over AVG and HC of 16% and 70%, respectively.4 Simi-
larly, in 2012, DeSilva et al reported mortality rates of
15.4%, 22.6%, and 36.8% among 82,202 patients initiating
dialysis with AVF, AVG, and HC, respectively.21 When
stratiﬁed into age categories of 70 to 80 years, 81 to
90 years, and >90 years, AVF was consistently superior
to HC for all groups, but the beneﬁt of AVG over HC
was lost among patients aged >90 years. This was in
contrast to the above-mentioned 2013 DeSilva study
showing no differences with AVG vs AVF in a patient
cohort$67 years of age22 but in direct support of the ﬁnd-
ings that we report in which the mortality beneﬁts of AVG
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ability of mortality with AVF vs AVG or HC reported in
the elderly population may be indicative of the wide range
of conditions that are likely to exist in an older cohort of
patients and highlights the importance of individualized
patient care, particularly in this age group.14
The limitations of the current study include its retro-
spective design and our use of an “incident dialysis access”
analysis approach that does not account for changes in ac-
cess methods over time. By excluding patients with mortal-
ity within 90 days of the start of dialysis, we aimed to
minimize biases introduced by missing data or early death
that is likely more attributable to the patient’s condition
than to access type. Vascular access types have been noted
to change over time, especially within 6 months of initia-
tion of dialysis,8 but we chose to follow an intention-to-
treat approach to address the effects of age on mortality
outcomes based on initial dialysis access used. The reason
for doing this was mainly to address previous assertions
within the elderly population that older patients may
appropriately receive HC for dialysis initiation, with the
thought that they can transition to permanent access if
they survive to that point rather than receive an unneces-
sary AVF that will never be used.15 However, we note a
signiﬁcant beneﬁt with AVF over both AVG and HC
even among the octogenarian and nonagenarian age
groups, and because we analyzed all patients with HC
and maturing AVF or AVG as being in the HC group,
we actually probably underestimated the relative mortality
beneﬁts with these approaches. In our previous work, we
demonstrated a consistent mortality beneﬁt with AVF
and AVG even over that of patients with HC and maturing
AVF (HR, 0.77; P < .001) and AVG (HR, 0.90; P < .001)
(Malas et al, in press). Therefore, if we had stratiﬁed pa-
tients within the current HC group into HC only vs HC
with maturing AVF vs HC with maturing AVG, the mor-
tality beneﬁts of AVF and AVG that we report would likely
have been even higher. Finally, we evaluated all-cause mor-
tality to remain consistent with prior age-related studies on
dialysis access types.4,21,23,24,32 Additional studies investi-
gating renal-speciﬁc mortality and mortality during a
longer time (ie, 5-year mortality) would be useful in delin-
eating whether the age-related changes we observe are due
to dialysis-speciﬁc differences or otherwise.33
CONCLUSIONS
In the current study, we demonstrate that age has a sig-
niﬁcant effect on all-cause mortality with different types of
dialysis access. AVF was superior to AVG and HC for all
age groups, including among the elderly. In contrast, the
mortality beneﬁts of AVG over HC appear to be restricted
to patients aged 49 to 89 years. This is the ﬁrst study that
we know of to report a changing beneﬁt with AVG vs HC
depending on the patient’s age. On the basis of these ﬁnd-
ings, we recommend an emphasis on the need for a consis-
tent Fistula First approach in all patients, including those at
the younger and older extremes of age. If autogenous ac-
cess is not possible in younger (18-48 years) and older(>89 years) patients, AVG should not be considered supe-
rior to HC. Younger patients lacking an autogenous access
should be considered for expedition on the transplant list.
Although patient-level factors will ultimately determine
the most appropriate form of dialysis access for each indi-
vidual, quality improvement strategies including early
nephrologist and surgery referral and use of preoperative
duplex ultrasonography may help improve maturation rates
that allow dialysis initiation with AVF and ultimately
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excluded the transition from catheter to ﬁstula or graft? You said
these were patients on chronic dialysis. Did you say it was more
than 6 months, or how was it that you deﬁned the fact that they
weren’t just starting dialysis and they were going to move on?
Dr Mahmoud B. Malas. Information on patient characteris-
tics was obtained from the Centers for Medicare and Medicaid Ser-
vices Form 2728. This form, completed by physicians and dialysis
unit nurses, speciﬁcally excludes patients with acute renal failure.
We excluded all patients who died within 3 months from dialysis
initiation and all patients with prior access.
Dr Dalman. There is, however, some possibility that some of
these patients are transitioning to another form of dialysis?
Dr Malas. Absolutely. However, we performed subgroup
analysis for patients initiating dialysis with catheter while having
maturing ﬁstula or graft. Not surprisingly, they did better than pa-
tients who had a catheter only and worse than patients who already
had a mature ﬁstula or graft. This is likely a reﬂection of transition-
ing to permanent access at some point during the study period.
The limitation of our study is the inability to determine when
this transition occurred. Our intention-to-treat analysis likely
underestimated the mortality associated with catheter since many
of these patients eventually transitioned to permanent access.
Dr Ahmed Abou-Zamzam (Loma Linda, Calif). Is this really
just a marker for better health care prior to dialysis? The people
who have the ﬁstulas have anticipatory health care that is identi-
fying them early as potentially progressing to end-stage renal dis-
ease, so you’re selecting out a well-cared-for population vs a
population that didn’t get prior health care.
DrMalas.Health care, nephrology care, and insurance coverage
were all independent predictors of establishing permanent access.However, the surprising ﬁnding in this study was that many of
the patients dialyzed through catheter did have proper insurance
coverage and access to health care prior to dialysis. The survival
beneﬁt of autogenous access persisted after adjusting for age,
gender, race, comorbidities, and insurance status. With the four
different matching techniques we used in our analysis, we
conﬁrmed that over 90% of patients initiating hemodialysis with
catheter match patients initiating hemodialysis with ﬁstula or graft
based on age, gender, race, comorbidities, and insurance coverage.
Dr Matthew Langenberg (Willoughby, Ohio). Do you, or the
committee, have any thoughts or suggestions on ways we can
engage our nephrology colleagues in hopes of more timely
referrals?
Dr Malas. Propensity score analyses showed that nephrology
care increases the patient’s chance of getting a ﬁstula by 11-fold. I
believe there are several interventions we can do to achieve the Fis-
tula First Breakthrough Initiative recommendations. First, we need
to establish better communication with our colleagues in
nephrology. Second, we need to better educate our patients and
involve them in the decision making. The third component is
our responsibility as surgeons to perform timely proper access
type customized for each one of our patients.
Dr Ravi Veeraswamy (Atlanta, Ga). Just a quick question
about the data. Is this placement of access or successful access?
In other words, if they get a ﬁstula and it doesn’t mature and
then they get a catheter and that’s what they use for their ﬁrst dial-
ysis, how is that catheter.
Dr Malas. For this analysis, we excluded all patients with any
prior access types including the nonsuccessful ones. Every patient
included in this study is having initial dialysis for chronic renal fail-
ure through his or her ﬁrst catheter, graft, or ﬁstula.
